Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

NCT05209308 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Discontinuation of zandelisib development

Conditions

CLL

Interventions

DRUG: Zandelisib
DRUG: Rituximab
DRUG: Venetoclax

Sponsor

MEI Pharma, Inc.

Collaborators

[object Object]